Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/identification-of-nitazoxanide-as-a-group-i-metabotropic-glutamate-k0JVnsOKyU
References (41)
-
G. Law, Jennifer Tisoncik-Go, M. Korth, M. Katze (2013)
Drug repurposing: a better approach for infectious disease drug discovery?Current Opinion in Immunology, 25
-
A. Corbett, Gareth Williams, C. Ballard (2013)
Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s DiseasePharmaceuticals, 6
-
S. Chaki, Y. Ago, Agnieszka Palucha-Paniewiera, F. Matrisciano, Andrzej Pilc (2013)
mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressantsNeuropharmacology, 66
-
B. Korba, A. Montero, Kristine Farrar, K. Gaye, Sampa Mukerjee, M. Ayers, J. Rossignol (2008)
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.Antiviral research, 77 1
-
R. Zauhar, Eleonora Gianti, W. Welsh (2013)
Fragment-based Shape Signatures: a new tool for virtual screening and drug discoveryJournal of Computer-Aided Molecular Design, 27
-
S. D’Antoni, M. Spatuzza, C. Bonaccorso, S. Musumeci, L. Ciranna, F. Nicoletti, K. Huber, M. Catania (2014)
Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and AutismNeuroscience & Biobehavioral Reviews, 46
-
A. Corbett, Gareth Williams, C. Ballard (2015)
Drug repositioning in Alzheimer's disease.Frontiers in bioscience, 7
-
R. Braga, C. Andrade (2013)
Assessing the performance of 3D pharmacophore models in virtual screening: how good are they?Current topics in medicinal chemistry, 13 9
-
S. Chiechio, F. Nicoletti (2012)
Metabotropic glutamate receptors and the control of chronic pain.Current opinion in pharmacology, 12 1
-
J. Rocher, Béatrice Bonnet, C. Boléa, R. Lütjens, E. Poul, S. Poli, M. Epping-Jordan, A. Bessis, B. Ludwig, V. Mutel (2011)
mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents.Current topics in medicinal chemistry, 11 6
-
V. Law, Craig Knox, Yannick Djoumbou, Timothy Jewison, Anchi Guo, Yifeng Liu, Adam Maciejewski, David Arndt, Michael Wilson, V. Neveu, Alexandra Tang, Geraldine Gabriel, Carol Ly, Sakina Adamjee, Zerihun Dame, B. Han, You Zhou, D. Wishart (2013)
DrugBank 4.0: shedding new light on drug metabolismNucleic Acids Research, 42
-
A Corbett, J Pickett, A Burns, J Corcoran, SB Dunnett, P Edison (2012)
Drug repositioning for Alzheimer’s diseaseNat Rev Drug Discov, 11
-
C. Wang, Ni Ai, S. Arora, E. Erenrich, Karthigeyan Nagarajan, R. Zauhar, Douglas Young, W. Welsh (2006)
Identification of previously unrecognized antiestrogenic chemicals using a novel virtual screening approach.Chemical research in toxicology, 19 12
-
S. Kortagere, D. Chekmarev, W. Welsh, S. Ekins (2008)
New Predictive Models for Blood–Brain Barrier Permeability of Drug-like MoleculesPharmaceutical Research, 25
-
Ruili Huang, Noel Southall, Yuhong Wang, Adam Yasgar, P. Shinn, A. Jadhav, Dac-Trung Nguyen, C. Austin (2011)
The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical GenomicsScience Translational Medicine, 3
-
M. Osikowicz, J. Mika, B. Przewłocka (2013)
The glutamatergic system as a target for neuropathic pain reliefExperimental Physiology, 98
-
R. Zauhar, G. Moyna, L. Tian, Zhijiang Li, W. Welsh (2003)
Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design.Journal of medicinal chemistry, 46 26
-
I. Hartman, Alison Gillies, S. Arora, Christina Andaya, Nitya Royapet, W. Welsh, D. Wood, R. Zauhar (2009)
Application of Screening Methods, Shape Signatures and Engineered Biosensors in Early Drug Discovery ProcessPharmaceutical Research, 26
-
J. Pin, C. Colle, A. Bessis, F. Acher (1999)
New perspectives for the development of selective metabotropic glutamate receptor ligands.European journal of pharmacology, 375 1-3
-
F. Nicoletti, J. Bockaert, G. Collingridge, P. Conn, F. Ferraguti, D. Schoepp, J. Wroblewski, J. Pin (2011)
Metabotropic glutamate receptors: From the workbench to the bedsideNeuropharmacology, 60
-
L. Pomierny-Chamioło, K. Rup, B. Pomierny, Ewa Niedzielska, P. Kalivas, M. Filip (2014)
Metabotropic glutamatergic receptors and their ligands in drug addiction.Pharmacology & therapeutics, 142 3
-
F. Ribeiro, M. Paquet, S. Cregan, S. Ferguson (2010)
Group I metabotropic glutamate receptor signalling and its implication in neurological disease.CNS & neurological disorders drug targets, 9 5
-
Conn Pj, J. Pin (1997)
Pharmacology and functions of metabotropic glutamate receptors.Annual review of pharmacology and toxicology, 37
-
U. Bharadwaj, T. Eckols, Mikhail Kolosov, Moses Kasembeli, A. Adam, David Torres, Xiaomei Zhang, L. Dobrolecki, Wei Wei, M. Lewis, B. Dave, Jenny Chang, M. Landis, C. Creighton, M. Mancini, D. Tweardy (2014)
DRUG-REPOSITIONING SCREENING IDENTIFIED PIPERLONGUMINE AS A DIRECT STAT3 INHIBITOR WITH POTENT ACTIVITY AGAINST BREAST CANCEROncogene, 34
-
Karthigeyan Nagarajan, R. Zauhar, W. Welsh (2005)
Enrichment of Ligands for the Serotonin Receptor Using the Shape Signatures ApproachJournal of chemical information and modeling, 45 1
-
M. Hurle, Lun Yang, Qing Xie, D. Rajpal, P. Sanseau, Pankaj Agarwal (2013)
Computational Drug Repositioning: From Data to TherapeuticsClinical Pharmacology & Therapeutics, 93
-
S. Choi, M. Son (2011)
Novel botanical drug for the treatment of diabetic neuropathyArchives of Pharmacal Research, 34
-
Hua Fan-Minogue, Sandhya Bodapati, D. Solow-Cordero, A. Fan, R. Paulmurugan, T. Massoud, D. Felsher, S. Gambhir (2013)
A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of NitazoxanideMolecular Cancer Therapeutics, 12
-
J. Rautio, Hanna Kumpulainen, T. Heimbach, R. Oliyai, Dooman Oh, T. Järvinen, J. Savolainen (2008)
Prodrugs: design and clinical applicationsNature Reviews Drug Discovery, 7
-
S. Kulkarni, M. Zou, Jianjing Cao, J. Deschamps, Alice Rodriguez, P. Conn, A. Newman (2009)
Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.Journal of medicinal chemistry, 52 11
-
Ankur Vaidya, Shweta Jain, A. Jain, A. Agrawal, S. Kashaw, S. Jain, R. Agrawal (2013)
Metabotropic glutamate receptors: a review on prospectives and therapeutic aspects.Mini reviews in medicinal chemistry, 13 13
-
C. Lindsley, Brittney Bates, Usha Menon, S. Jadhav, Alexander Kane, Carrie Jones, Alice Rodriguez, P. Je, R. Conn, C. Olsen, D. Winder, K. Emmitte (2011)
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction.ACS chemical neuroscience, 2 8
-
D. Owen (2011)
Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu₁).ACS chemical neuroscience, 2 8
-
S. Kortagere, D. Chekmarev, W. Welsh, S. Ekins (2009)
Hybrid Scoring and Classification Approaches to Predict Human Pregnane X Receptor ActivatorsPharmaceutical Research, 26
-
Is it true FDA is approving fewer new drugs lately? www.fda.gov/AboutFDA -
N. Pitsikas (2014)
The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?European journal of pharmacology, 723
-
S. Ekins, Antony Williams (2011)
Finding Promiscuous Old Drugs for New UsesPharmaceutical Research, 28
-
D. Chekmarev, V. Kholodovych, S. Kortagere, W. Welsh, S. Ekins (2009)
Predicting Inhibitors of Acetylcholinesterase by Regression and Classification Machine Learning Approaches with Combinations of Molecular DescriptorsPharmaceutical Research, 26
-
N. Tejman-Yarden, Y. Miyamoto, D. Leitsch, J. Santini, A. Debnath, J. Gut, J. McKerrow, S. Reed, L. Eckmann (2013)
A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant Giardia lambliaAntimicrobial Agents and Chemotherapy, 57
-
B. Readhead, J. Dudley (2013)
Translational Bioinformatics Approaches to Drug Development.Advances in wound care, 2 9
-
L. Bastos, M. Coelho (2013)
Drug Repositioning: Playing Dirty to Kill PainCNS Drugs, 28
- Publisher
- Springer Journals
- Copyright
- Copyright © 2015 by Springer Science+Business Media New York
- Subject
- Biomedicine; Pharmacology/Toxicology; Pharmacy; Biochemistry, general; Medical Law; Biomedical Engineering
- ISSN
- 0724-8741
- eISSN
- 1573-904X
- DOI
- 10.1007/s11095-015-1665-7
- pmid
- 25762088
- Publisher site
- See Article on Publisher Site
Abstract
The major aim of the present study was to demonstrate the utility of an in silico-in vitro-in vivo drug repositioning protocol to facilitate the repurposing of approved drugs for new therapeutic indications. As an example, this particular investigation successfully identified nitazoxanide and its metabolite tizoxanide as dual mGluR1/5 negative modulators. A key finding is the vital importance for drug screening libraries to include the structures of drug active metabolites, such as those emanating from prodrugs which are estimated to represent 5–7% of marketed drugs.
Journal
Pharmaceutical Research – Springer Journals
Published: Mar 12, 2015